Blog

Nxera Pharma Webinar Presentation for Q2 FY2024 Financial Results

Jul 9, 2024 | blog

Tokyo, Japan and Cambridge, UK, 9 July 2024 – Nxera Pharma Co. Ltd (Nxera; TSE 4565) will announce its earnings outcomes and current operational highlights for the 6 months ended 30 June 2024 on Friday, 9 August 2024.

The Company will host a stay webinar presentation with Chris Cargill, President and CEO, Hironoshin Nomura, CFO, Matt Barnes, EVP, President of Nxera Pharma UK, Head of R&D and Satoshi Tanaka, EVP, President of Nxera Pharma Japan at 4:30 pm JST (8:30 am BST) on Friday, 9 August 2024.

The webinar is open to all present and potential buyers in addition to sell-/buy-side analysts and can encompass a presentation adopted by a Q&A session. Please click on right here to pre-register, which can present a hyperlink to entry the webinar.

Presentation slides shall be made out there by 4 pm JST (8 am BST) on 9 August 2024 by means of the investor part of the Company’s Home Page right here.

“ ENDS “

About Nxera Pharma

Nxera Pharma (previously Sosei Heptares) is a expertise powered biopharma firm, in pursuit of recent specialty medicines to enhance the lives of sufferers with unmet wants in Japan and globally.

In addition to a number of merchandise being commercialized in Japan, we’re advancing an intensive pipeline of over 30 lively packages from discovery by means of to late scientific stage internally and in partnership with main pharma and biotech corporations. This pipeline is targeted on addressing main unmet wants in among the fastest-growing areas of medication throughout neurology, GI and immunology, metabolic problems and uncommon illnesses, and leverages the facility of our distinctive and trade main GPCR-targeted structure-based drug discovery NxWave™ platform to supply a sustainable supply of best- or first-in-class candidates.

Nxera employs over 350 proficient individuals at key areas in Tokyo and Osaka (Japan), London and Cambridge (UK), Basel (Switzerland) and Seoul (South Korea) and is listed on the Tokyo Stock Exchange (ticker: 4565).

For extra data, please go to www.nxera.life
LinkedIn: @NxeraPharma | X: @NxeraPharma | YouTube: @NxeraPharma

Enquiries:

Nxera Pharma
Kentaro Tahara, VP Investor Relations and Corporate Strategy
Shinichiro Nishishita, VP Investor Relations, Head of Regulatory Disclosures
Maya Bennison, Communications Manager
+81 (0)3 5210 3399 | +44 (0)1223 949390 | IR@Nxera.life

MEDiSTRAVA (for International Media)
Mark Swallow, Frazer Hall, Erica Hollingsworth
+44 (0)203 928 6900 | Nxera@medistrava.com

Forward-looking statements

This press launch accommodates forward-looking statements, together with statements concerning the discovery, growth, and commercialization of merchandise. Various dangers could trigger Nxera Pharma Group’s precise outcomes to vary materially from these expressed or implied by the ahead trying statements, together with: adversarial leads to scientific growth packages; failure to acquire patent safety for innovations; business limitations imposed by patents owned or managed by third events; dependence upon strategic alliance companions to develop and commercialize services and products; difficulties or delays in acquiring regulatory approvals to market services and products ensuing from growth efforts; the requirement

for substantial funding to conduct analysis and growth and to develop commercialization actions; and product initiatives by rivals. As a results of these components, potential buyers are cautioned to not depend on any forward-looking statements. We disclaim any intention or obligation to replace or revise any forward-looking statements, whether or not because of new data, future occasions or in any other case.

Source: Nxera Pharma
MoneyMaker FX EA Trading Robot

powered by qhost365.com

Investing.com